【歌礼制药-B(01672.HK):歌礼将携口服小分子GIPR激动剂ASC48和GLP-1R/GIPR/GCGR三靶点激动剂多肽ASC37的研究结果亮相2026年肥胖周(ObesityWeek®)】智通财经APP讯,歌礼制药-B(01672.HK)发布公告,其肥胖症管线口服小分子GIPR激动剂ASC48和GLP-1R/GIPR/GCGR三靶点激动剂多肽ASC37的两篇壁报将在2026年肥胖周(ObesityWeek®)上展示。该会议将于2026年11月14日至17日在美国华盛顿特区举行。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.